There will be even more companies playing in the stand-alone drug insurance market in 2007. The new entrants are motivated more by fear than enthusaism. Still, the rush to get in is the strongest indication yet that Part D is here to stay.
By Michael McCaughan
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
The biotech CEO said the Trump Administration’s treatment of FDA employees, including the HHS secretary’s comments about industry capture, are insulting to agency staff, but he is encouraged by FDA Commissioner Martin Makary’s talk of a new conditional approval pathway.
Manufacturers are engaging the European Commission and individual countries to allocate more health care spending to innovative medicines and align prices more closely to those in the US.
Blood cancer therapies were most proportionately impacted by the failure of pharmaceutical companies to submit evidence on their cancer therapies to England’s health technology appraisal body, shows analysis by the Pink Sheet.
Employers and other health plan sponsors may need to push for better targeted reforms that lower cost sharing for patients.
Finding ways to lower the rebates paid by the pharmaceutical industry to the UK government and fostering partnerships to make the UK a more attractive launch market could help reduce the number of terminated technology appraisals conducted by NICE, the health technology appraisal institute, says the UK pharmaceutical industry.
Blood cancer therapies were most proportionately impacted by the failure of pharmaceutical companies to submit evidence on their cancer therapies to England’s health technology appraisal body, shows analysis by the Pink Sheet.
Employers and other health plan sponsors may need to push for better targeted reforms that lower cost sharing for patients.
